Related Experiment Videos
Advances in interleukin 2 receptor targeted treatment
1Metabolism Branch, Division of Clinical Sciences, National Cancer Institute, NIH, Bldg 10, Rm 4N115, 10 Center Drive, Bethesda, MD 20892-1374, USA. jmorris@mail.nih.gov
Annals of the Rheumatic Diseases
|October 29, 2000
Summary
Interleukin 2 receptor alpha (IL2Ralpha), also known as CD-25, is a marker of T cell activation. Targeting IL2Ralpha with humanized anti-Tac antibodies shows promise in preventing transplant rejection and treating lymphomas.
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- Interleukin 2 (IL2) signaling is crucial for T cell activation and immune responses.
- The high-affinity IL2 receptor (IL2Ralpha/CD25) is upregulated on activated T cells.
- Soluble IL2Ralpha (s-Tac) in serum serves as a marker for T cell activation.
Purpose of the Study:
- To investigate the role of IL2Ralpha in immune responses and disease.
- To evaluate the therapeutic potential of targeting IL2Ralpha.
Main Methods:
- Analysis of IL2Ralpha expression on T cells.
- Measurement of soluble IL2Ralpha (s-Tac) in serum.
- Development and testing of anti-Tac monoclonal antibodies, including humanized versions (HAT).
- Assessment of HAT in allograft rejection and graft-versus-host disease models.
- Exploration of IL2Ralpha-targeted therapies like radioimmunoconjugates and immunotoxins.
Main Results:
- IL2Ralpha is overexpressed in autoimmune diseases, allograft rejection, and lymphoid neoplasms.
- Humanized anti-Tac (HAT) effectively reduces renal and cardiac allograft rejection.
- HAT decreases the severity of graft-versus-host disease post-transplantation.
- IL2Ralpha-targeted agents show potential for treating CD25-expressing lymphomas.
Conclusions:
- IL2Ralpha is a significant therapeutic target in immune-mediated diseases and cancers.
- Targeting IL2Ralpha with agents like HAT offers a promising strategy for immunosuppression and cancer therapy.